Hypolipidemic and Hepatoprotective Effects of Myricitrin and Solid Lipid Nanoparticlecontaining Myricitrin on the Male Mouse Model with Type 2 Diabetes Induced by StreptozotocinNicotinamide

Background: Type 2 diabetes mellitus (T2DM) has several complications such as hyperlipidemia and hepatotoxicity. Myricitrin has an antidiabetic action along with low bioavailability. So, the aim of the present study was to investigate hypolipidemic and hepatoprotective effects of myricitrin and solid lipid nanoparticle (SLN) containing myricitrin on the T2DM mouse model induced by Streptozotocinnicotinamide (STZNA). lt;br / gt; Methods: lt;/strong gt; In this experimental study, 90 Naval Medical Research Institute (NMRI) adult male mice were divided into 9 groups (n=10 per group): control, vehicle, diabetic, diabetic + myricitrin, or SLN containing myricitrin 1, 3, and 10 mg/kg groups. The cold homogenization method was used to prepare SLN containing myricitrin. The diabetic model was induced by one injection of STZNA (65120 mg/kg) with a 15min interval. Animalsapos; treatment was done for 4 weeks. At the end of the experiment, plasma samples were taken for experimental assessments. lt;br / gt; Results: lt;/strong gt; Plasma level of triglyceride (TG), lowdensity lipoprotein (LDLC), verylowdensity lipoprotein (VLDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) increased and highdensity lipoprotein cholesterol (HDLC) decreased in diabetic mice compared to the control group (p lt;0.05). Administration of myricitrin or SLN containing myricitrin decreased plasma levels of TG, LDLC, VLDL, AST, and ALT and increased HDLC in the treated diabetic groups compared to the untreated groups (p lt;0.05). Conclusion: According to the results, myricitrin and SLN containing myricitrin showed hypolipidemic and hepatoprotective effects in T2DM mice. Also, SLN containing myricitrin was more potent than myricitrin especially in a low dose of administration.